Company ProfilePremium

BPH Energy Limited

Company Profile Analysis

Ticker: BPH.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
BPH Energy Limited - Company showcase

Year Founded & Workforce

2001

2 Employees

BPH Energy Limited logo

BPH Energy Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BPH Energy Limited Overview

BPH Energy Limited is a Perth-based, ASX-listed investment holding company. It raises equity from public markets and deploys it, mainly through loans and minority equity stakes, into a small portfolio of unlisted Australian and international ventures. These span upstream gas exploration, clean-hydrogen technology and medical devices.

Its economic value is dominated by one asset: a 35.8% stake in, and a large loan book to, Advent Energy Limited. Advent's subsidiary Asset Energy holds 85% of Petroleum Exploration Permit PEP-11 in the offshore Sydney Basin. PEP-11 carries a P50 prospective resource of 5.7 Tcf gross, of which Advent's net share is 4.9 Tcf. The permit's extension was refused by the Commonwealth–NSW Joint Authority, a refusal upheld by the Federal Court in June 2026 and now under appeal.

Secondary holdings are:

  • Cortical Dynamics (16.3%): developer of the BARM 2.0 AI-enabled brain and pain monitor.

  • Clean Hydrogen Technologies Corporation (16.1%): methane pyrolysis producing turquoise hydrogen and carbon nanotubes.

  • Molecular Discovery Systems (20%): liver-cancer gene research.

The company is effectively a leveraged legal and regulatory option on PEP-11, alongside venture-stage biotech and hydrogen exposures. It trades at a deep discount to book value.


Company's own description (FY26 AR, Review of Operations)

The FY26 AR describes BPH as a company that uses funds raised to provide financial support to, and make direct investments in, a number of investees, associates and related companies. These include Advent Energy Limited, Cortical Dynamics Limited, MEC Resources Limited and Clean Hydrogen Technologies Corporation.

The Directors' Report defines principal activities as "investments in biotechnology and oil and gas exploration entities". Under future developments, the company says it will continue investing in energy resources and helping investees commercialise biomedical research developed in universities, medical institutes and hospitals.

Independent characterisation

BPH is best described as a listed closed-end venture vehicle with three features:

  1. Concentrated related-party financing. BPH's main use of cash is lending to Advent Energy, a company whose board includes BPH's chairman, David Breeze.

    • Loans advanced were A$3.68m in FY25 and A$3.66m in FY26.

    • Over FY22–FY26, about A$15.7m was advanced in total, against about A$4.9m repaid (FY22, FY25 and FY26 cash flow statements; FY23–FY24 loan detail not separately verified).

    • Interest accrues on these loans and forms most of BPH's reported "finance income".

  2. Fair-value-driven earnings. Reported profits in FY24 and FY25 came from fair-value gains on unlisted holdings (A$6.93m in FY25) and equity-accounted results, not from cash revenues. The FY26 loss was driven by a A$7.02m expected credit loss provision and a swing in associate results.

  3. Equity-funded overhead. The company has no operating cash inflows apart from interest receipts (A$127k in FY26). Corporate overhead and investee funding are met by recurring share and option issues.

Revenue model

Revenue typeShare of FY26 "finance income"Comment
Product sales0%—
Services0%None. An earlier biomedical-services description in aggregator profiles is not reflected in current filings
Subscription / licensing0%None at the BPH level
Interest income on loans to investees and on cash100% of A$1,042,417Mostly accrued (non-cash) interest. Only A$127,279 of interest was received in cash in FY26

Value-chain position, customers and end-markets

End-marketExposure route
East-coast Australian natural gasVia Advent / PEP-11
Northern Australia onshore gasVia Advent's Onshore Energy subsidiary, now under a Deed of Company Arrangement
Low-carbon hydrogen and battery-grade conductive carbon (India, USA, Singapore)Via Clean Hydrogen Technologies
Anaesthesia and critical-care brain monitoring (global medtech)Via Cortical Dynamics
Oncology diagnostics and therapeutics researchVia Molecular Discovery Systems

BPH sits at the capital-provision end of the value chain. It has no customers in the conventional sense. Its "counterparties" are its investees. The end-markets it is exposed to indirectly are:

Strategy

Stated strategy themes (FY26 AR)

  1. Continue investment in energy resources.

  2. Help investee companies commercialise "breakthrough biomedical research" from universities, medical institutes and hospitals.

  3. Through Advent, support NSW energy security with gas located closest to Australia's largest domestic market. Gas is positioned as firming support for renewables, with optional carbon capture and storage exploration offshore NSW, aligned with Net Zero 2050.

Initiatives in the last 24 months

DateInitiativeDetail
Aug 2024 → Jul 2026PEP-11 litigation programmeThree judicial and appellate actions (Aug 2024 mandamus; Feb 2025 review; Jul 2026 appeal), plus a Mar 2025 renewal application over 50% of the area
Mid-2024 → 2026CHT commercialisationIndian production facility design; ASME and IS2825 certification; Horizon Fuel Cells LOI; Singapore electricity generation company letter of support; planned NASDAQ SPAC listing
1 Jan 2026CHT option resetNew 5-year options at US$3,000 replace exercised seed options; 760 outstanding
FY25–FY26Cortical US strategyUS advisory team formed: Lt Gen Roger Cloutier (Ret) and Brig Gen Shan Bagby (Ret). Detroit investor presentations; Henry Ford Health engagement; Mayo Clinic presentation (Mar 2026)
FY26BARM 2.0 and CORDYAN™MVP completion, safety testing, then US and Netherlands trials
Oct 2025 → Feb 2026Option reloading622m expired 3c options replaced by new 3c options (542.9m issued at A$0.001, plus 10.7m to directors). Placement attaching and broker options lift the Feb 2027 series to 710.7m
Jan 2026A$1.208m placementUse of funds: A$0.85m oil and gas, A$0.25m Cortical, A$0.1m working capital
Apr–Jul 2026Onshore Energy restructuringVoluntary administration, then Deed of Company Arrangement

Cost programmes: no formal programme or target disclosed. Administration costs fell 25% in FY26.

ESG commitments: none at the BPH level beyond Advent's stated Net Zero 2050 support.

Medium-term financial targets or guidance: none disclosed.

Products & Services

BPH sells no products. Its "portfolio" is the asset and technology set of its investees, catalogued below.

Energy: Advent Energy (BPH 35.8%)

PEP-11, offshore Sydney Basin (Asset Energy 85%, Bounty Oil & Gas NL 15%)

Area and location: about 4,649 km², offshore the lower Hunter region, NSW. Prospects lie generally less than 50 km from the Sydney–Wollongong–Newcastle metropolitan area and gas pipeline network. It is the only petroleum title offshore NSW.

Resource: total P50 prospective resource of 5.7 Tcf, with 4.9 Tcf net to Advent (FY26 AR). This compares with 5.9 Tcf gross and 5.0 Tcf net in the FY22 4E, a downward revision not explained in the reviewed documents. Flagship prospects are Fish and Baleen. Baleen was ranked highest probability of success by the 2010 geochemical study.

Technical basis: - 2004 2D seismic data reprocessed in 2010, showing hydrocarbon-related diagenetic zones, amplitude-versus-offset anomalies and potential flat spots.

  • One well, New Seaclem-1 (2010).

Status: extension and variation applications refused (17 Jan 2025). Judicial review dismissed (17 Jun 2026). Appeal to the Full Court lodged (13 Jul 2026). A separate renewal application over 50% of the area is pending with NOPTA (lodged Mar 2025).

Carrying value at risk: Asset Energy carries capitalised exploration and evaluation expenditure of A$16.8m. This must be written off if tenure is lost (FY26 AR risk section).

Stated secondary use: carbon capture and storage exploration offshore NSW. Advent states support for Net Zero by 2050.

EP386 and RL1, onshore Bonaparte Basin (Onshore Energy 100%)

  • RL1 covers 166 km² over the Weaber Gas Field, discovered in 1985. RISC-audited contingent resources are 11.5 Bcf (2C) and 45.8 Bcf (3C) (FY22 4E).

  • A market study cited up to 30.8 TJ/day of potential Kimberley power-generation demand.

Status: Onshore Energy entered voluntary administration on 10 Apr 2026 (administrator Bryan Hughes, 101 Advisory). A Deed of Company Arrangement was approved on 24 Jul 2026, and a proposal was sent to the WA Department of Mines (DMPE).

Taranaki Basin farm-in (Aotearoa Offshore Ltd)

  • Right to a 30% interest in PEP 57075, 60092 and 60093 (5,180 km²) from OMV NZ under a farm-out agreement signed 24 Dec 2021.

  • BPH lent Advent A$3.0m for related payments in 2022.

  • Current status is not publicly disclosed in the FY26 AR.

Clean energy technology: Clean Hydrogen Technologies Corp (BPH 16.1%)

AttributeDetail (FY26 AR)
Core processMethane pyrolysis using a patented catalyst in a modified fluidised-bed reactor. Average cracking efficiency of 92% at proof-of-concept scale. No CO₂ emitted in the core process and no water used
ProductsTurquoise hydrogen, and a carbon composite that is mostly carbon nanotubes (CNT) and carbon nanofibres. The CNT composite represents most of CHT's projected revenue
Pilot plantNashik, India. Consistent two-product output demonstrated from mid-2024
First commercial plant designMaharashtra, India. Stage 1 capacity of 820 t/yr hydrogen and 2,462 t/yr carbon composite. Louisiana, USA is a likely second site
Engineering certificationASME (USA) and IS2825 (India) design reviews "almost complete"
Commercial pipelineMOU-stage discussions on CNT use in grid-scale batteries and cement. Letter of support from a Singapore electricity generation company (Jurong Island low-carbon data centres). Letter of Intent with Horizon Fuel Cells for hydrogen supply to US data-centre fuel cells
Corporate planCapital raise at US$3,000 per share for up to US$2.5m, expected by Nov 2026. Intended NASDAQ listing via a special-purpose acquisition company (SPAC)
BPH options760 options outstanding at US$3,000, with 5-year expiry from replacement on 1 Jan 2026. 139 original options exercised
Pricing model—

Medical technology: Cortical Dynamics Ltd (BPH 16.3%)

ProductDescriptionStatus
BARM™ (first generation)EEG-based brain anaesthetic response monitor whose index is grounded in brain physiology. Focus on total intravenous anaesthesia (TIVA)TGA approval, Korean MFDS approval and CE mark obtained. FDA 510(k) process started in 2022 with advisers MCRA (FY22 4E). Patent position (2022): 5 families, 36 granted patents
BARM 2.0Next-generation AI-enhanced monitor that, per the company, is the only system unifying hypnotic depth and pain-response monitoring in one EEG plus AI platformMinimum viable product "nearing completion". Then electromagnetic compatibility and electrical safety testing. Clinical trials planned in the USA and the Netherlands, followed by worldwide regulatory submissions
BarSensors™Proprietary new EEG sensors for BARM 2.0Biocompatibility and ageing (shelf-life) testing pending
CORDYAN™AI and deep-learning predictive medical apps, usable standalone, with BARM 2.0, or integrated into hospital systems and electronic medical recordsIn development, supported by matched grants from MTPConnect and ARM Hub

Target customers: anaesthetists, hospitals and health systems; later ICU, neurodiagnostics and drug evaluation.

Pricing: not publicly disclosed.

Biotechnology: Molecular Discovery Systems Ltd (BPH 20%)

  • Validates HLS5 (TRIM35) as a tumour-suppressor gene in liver cancer (hepatocellular carcinoma) with the Harry Perkins Institute of Medical Research.

  • Supporting literature from Fudan University and other Chinese institutes describes an HLS5–PKM2 binding mechanism and a prognostic study of 688 patients.

  • No product, revenue or trial programme is disclosed.

  • BPH's investment is fully impaired. The gross loan receivable was A$1.54m at FY22, fully provided.

Financial Narrative

Basis: consolidated AASB/IFRS accounts. FY22, FY25 and FY26 come from primary filings. FY23 and FY24 income figures come from the FY26 AR five-year table. FY23 and FY24 balance sheet and cash flow figures come from aggregator data (InvestSMART, Stockopedia, Kalkine) and should be treated as approximate.

Income statement

How these figures were built:

  • Corporate overheads are the sum of administration and promotion, consulting and legal, directors' fees, service expenses and share-based payments. FY26: 417.2 + 225.4 + 100.0 + 128.6 + 481.5 = A$1,352.8k.

  • FY22 other income of A$68.1k (sub-underwriting fees) is included in the FY22 core result.

  • Gross profit is not applicable, as the company has no cost of sales.

  • EBITDA is approximately equal to pre-tax income: there is no depreciation or amortisation, interest expense was A$11 in FY26 and A$105 in FY22, and tax is nil in all years.

FY22, FY25 and FY26 ratios are company-reported (Appendix 4E). FY23 and FY24 are derived from the five-year table. Margins are not economically meaningful for an investment vehicle and are shown for completeness only.

Revenue CAGR FY22–FY26: about 61% per year (A$154.7k to A$1,042.4k). This growth is almost entirely accrued interest on the rising Advent loan book, not commercial revenue.

Commentary.

FY26 was the inflection year: BPH booked a A$7.02m expected credit loss, a A$2.22m share of associate losses (Advent, after the PEP-11 judgment and the Onshore Energy administration) and a A$0.64m fair-value loss. The 1H FY26 report attributes part of the fair-value loss to exchange-rate movements on the US$-denominated CHT holding.

Inferred attribution: The scale and timing of the credit-loss charge indicate it relates predominantly to Advent loan receivables after the 17 Jun 2026 judgment.

Cost discipline is visible: Administration and promotion fell 25% YoY (A$560k to A$417k), and the core cash-overhead line improved.

Balance sheet

Notes:

  • FY23 total assets, cash, current assets, liabilities and equity are aggregator-rounded (InvestSMART and Stockopedia).

  • FY24 cash, equity, issued capital and accumulated losses are taken from the FY26 AR statement of changes in equity and the FY25 cash flow opening balance. FY24 total assets and current assets are aggregator figures (Kalkine A$30.29m).

Commentary.

  • The balance sheet is almost entirely illiquid unlisted assets: about A$26.2m of A$31.2m (84%) at FY26 is non-current.

  • Cash has fallen in three consecutive years, from A$6.42m (FY24) to A$2.28m (FY26).

  • The group is debt-free apart from a A$65k interest-free borrowing.

  • A further A$625k of directors' fees has been accrued but not paid and sits within payables (A$521k at FY25). In effect, directors are financing the company.

Cash flow

Notes:

  • FY23 operating, investing and financing flows are from Stockopedia and Kalkine.

  • FY24 operating cash flow of −A$0.94m is from InvestSMART. FY24 investing (about −A$3m) and financing (about +A$5m) are reported only in rounded form by InvestSMART and are left blank here.

  • The FY26 loan repayment of A$876.6k was by Cortical Dynamics, on 5 Feb 2026, from its R&D tax incentive refund.

Commentary.

  • Operating burn has fallen each year since FY23, down 44% from FY23 to FY26.

  • The real cash drain is investing outflow, driven by recurring loans to Advent (about A$3.7m per year in FY25 and FY26).

  • The Jun-26 Appendix 4C reported 38.7 quarters of funding available. That metric covers operating outflows only and excludes discretionary investee lending, so it materially overstates the effective runway if Advent funding continues at FY26 rates.

  • At FY26 run-rates (about A$0.6m operating plus about A$2.8m net investing per year), the A$2.28m cash balance implies a need for new equity or a sharp reduction in Advent lending within FY27. This is an analyst inference.

Ratios

Notes:

  • FY22, FY25 and FY26 ROE are company-reported. Other ratios are analyst-derived from the tables above; FY23 and FY24 use aggregator balances.

ROIC: not meaningful (equity-funded, no operating invested capital).

Net debt / EBITDA: not meaningful (net cash, and EBITDA swings sign).

Interest coverage: not meaningful (interest expense of A$11 in FY26).

Asset turnover: about 0.03x in FY26 (finance income / total assets).

Cash conversion cycle: not applicable.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityBPH interestAccounting treatmentActivityDomicile

Advent Energy Ltd

35.8% direct (35.81% per Jul 2026 announcements)

Associate (equity method), plus loans at amortised cost

Oil and gas exploration

Australia (unlisted)

Asset Energy Pty Ltd

100% of Advent

Held via Advent

85% of PEP-11 and JV operator

Australia

Onshore Energy Pty Ltd

100% of Advent

Held via Advent; under Deed of Company Arrangement

EP386 and RL1 (Bonaparte Basin)

Australia

Aotearoa Offshore Ltd (NZ)

100% of Advent

Held via Advent

Taranaki farm-in vehicle (current status not disclosed)

New Zealand

Cortical Dynamics Ltd

16.3% (FY26 AR); 16.4% (Jun-26 quarterly); 17.7% (FY22)

Financial asset at fair value through profit or loss

Medical devices

Australia (unlisted)

Clean Hydrogen Technologies Corp

16.1%, plus 760 options at US$3,000

Financial asset at fair value through profit or loss

Hydrogen and carbon nanotubes

USA (unlisted)

Molecular Discovery Systems Ltd

20%

Associate, fully impaired

Cancer research

Australia (unlisted)

MEC Resources Ltd

Small listed shareholding plus secured loan (FY22)

Financial asset

Investment company

Australia (ASX-listed)

Controlled subsidiaries

—

Consolidated. Non-controlling interest was −A$165k at FY26

Not publicly disclosed in reviewed extracts

Australia

Revenue by Segment and Segment Assets & Liabilities

Category (AUD K)FY2022FY2025FY2026

Investments in associates (Advent and MDS)

3,9424,2262,029

Non-current financial assets (loans and FVTPL equity)

8,19324,21024,153

Current financial assets

1236,5672,676

Cash and equivalents

2,8954,0662,281

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Finance income / revenue (AUD K)

154.7304.1843.7836.61,042.4

Revenue growth YoY (%)

136.296.6177.5-0.824.6

Fair value gain/(loss) (AUD K)

0——6,930.2-639.9

Share of associates' profit/(loss) (AUD K)

-405.5——672.5-2,223.3

Expected credit losses (AUD K)

-88.4——-110.4-7,016.3

Corporate overheads incl. share-based payments (AUD K)

-824.4——-1,565.0-1,352.8

Core result: finance income + other income − overheads (AUD K)

-601.6——-728.4-310.4

EBITDA (AUD K)

-1,078.5——6,785.9-10,163.3

Pre-tax income (AUD K)

-1,078.6852.34,555.46,785.9-10,163.3

Net income (AUD K)

-1,078.6852.34,555.46,785.9-10,163.3

EPS basic (A$ cents)

-0.160.100.440.56-0.79

EPS diluted (A$ cents)

-0.16——0.54-0.79

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin metric

Margin metricFY2022FY2023FY2024FY2025FY2026

Pre-tax income / revenue (%)

-697280540811-975

Net margin (%)

-697280540811-975

Balance Sheet

Metric (AUD K)FY2022FY2023FY2024FY2025FY2026

Total assets

15,208.620,40030,29039,183.131,231.3

Cash and equivalents

2,895.05,6106,423.04,066.32,281.0

Total current assets

3,053.97,00010,32010,747.25,049.1

Non-current financial assets

8,193.0——24,210.024,153.0

Investments in associates

3,941.7——4,225.92,029.2

Total liabilities

908.8985985697.2801.1

Short-term debt (unsecured, interest-free borrowings)

104.8——84.865.0

Long-term debt

00000

Net debt (negative = net cash)

-2,790.2——-3,981.5-2,216.0

Total equity

14,299.819,40029,300.438,485.930,430.3

Goodwill and intangibles

00000

Working capital

2,145.2——10,050.04,248.0

Issued capital

58,844.6—66,360.567,563.068,592.4

Accumulated losses

-45,489.4—-40,079.0-33,292.1-43,455.1

Cash Flow

Metric (AUD K)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

-1,022.1-1,050.6-940-736.9-587.5

Capex

00000

Free cash flow (operating cash flow − capex)

-1,022.1-1,050.6-940-736.9-587.5

Investing cash flow

-6,257.6-217—-3,122.6-2,778.5

Loans advanced to investees

-4,740.8——-3,683.1-3,655.1

Loans repaid by investees

1,124.7——987.7876.6

Financing cash flow

1.43,990—1,502.81,580.7

Net equity proceeds

1.4——1,502.81,600.5

Dividends paid

00000

Buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (% of closing equity)

-7.54.415.517.6-33.4

ROA (% of closing total assets)

-7.14.215.017.3-32.5

Current ratio (x)

3.367.1110.4815.416.30

Debt / equity (%)

0.7——0.20.2

Results by Region

Region (AUD K)FY2024FY2025FY2026

Australia (finance income)

843.7836.61,042.4

Rest of world

000

Region Overview

RegionExposure

Australia

NSW (PEP-11), WA/NT (Bonaparte, now under DOCA), and Cortical and MDS in Victoria and WA

United States

CHT incorporation and its planned Louisiana site; Cortical's US commercial focus

India

CHT pilot plant in Nashik and the Stage 1 plant in Maharashtra

Singapore

CHT hydrogen opportunity

Netherlands

Planned BARM 2.0 trial site

New Zealand

Advent's Taranaki interest (status not disclosed)

Per-Share Data and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (A$ cents)

1.12.31.90.80.3

Shares on issue at year-end (millions)

664.9———1,350

Return period to 30 Jun 2026

Return period to 30 Jun 2026Total return

1 year

−62.5% (0.8c → 0.3c)

3 years

−87.0% (2.3c → 0.3c)

5 years

From FY22 (1.1c) the decline is −72.7%

Valuation Multiples

MultipleBPHComment

P/E

Not meaningful (FY26 loss)

Google Finance showed 1.49x on trailing FY25 profit earlier in 2026

P/B

about 0.13x

Market capitalisation about A$4.0m vs equity of A$30.4m

Price / NTA

about 0.14x

0.3c vs 2.2c NTA per share

EV / Sales

about 1.7x

EV about A$1.8m (market capitalisation minus net cash of A$2.2m) vs A$1.04m finance income

Capital Markets

ItemPosition

Analyst consensus

None (no coverage; StockAnalysis shows n/a)

Dividends

Nil in every year; no dividend policy

Buybacks

None authorised

Credit ratings

None (Moody's, S&P, Fitch: not rated)

Debt maturity profile

Only A$65k current, unsecured, interest-free borrowings

Next scheduled reports

Interim 16 Feb 2027; preliminary final 30 Aug 2027 (InvestSMART calendar). September quarter 4C due by 31 Oct 2026

Series Details

SeriesNumberExercise price (AUD)Expiry

December 2025 (directors)

10,664,4400.03

27 Dec 2026

February 2026 (prospectus, placement and broker)

710,668,2680.03

10 Feb 2027

November 2025 (Breeze)

5,000,0000.03

30 Nov 2026

November 2023

5,250,0000.05

7 Dec 2028

Performance rights (Breeze)

58,000,0000

30 Nov 2028

Analyst Conclusions

Management guidance and consensus

Management provides no financial guidance. The only forward statements are:

  • continued investment in energy and biomedical commercialisation;

  • the PEP-11 appeal, whose timing is "a matter for the Full Court";

  • CHT's capital raise by Nov 2026 and intended NASDAQ SPAC;

  • BARM 2.0 technical completion followed by trials in the USA and the Netherlands.

No analyst consensus exists.

Bull case

  1. Binary asymmetry on PEP-11. Market capitalisation of about A$4m against a 4.9 Tcf net prospective resource. The court accepted that procedural fairness was denied, giving appeal arguments substance, and a separate NOPTA renewal application over 50% of the area remains live.

  2. CHT liquidity event. A completed US$2.5m raise at US$3,000 per share and a SPAC listing would provide an external mark for BPH's 16.1% stake plus 760 options, which are valued on the balance sheet but unrealisable today.

  3. Deep discount to assets. Price is about 0.14x NTA, with debt-free status and a falling overhead base (A$0.59m operating burn in FY26). Even after the A$7m credit-loss reset, book equity is about 7.5 times market capitalisation.

Bear case

  1. The public-interest ground is near-dispositive. The court held refusal was independently justified on public-interest grounds, so overturning it on appeal is difficult. Loss of tenure removes A$16.8m of Advent's capitalised exploration and leaves BPH's remaining Advent exposure (A$2.0m associate carrying value plus residual loans) exposed to further impairment.

  2. Cash and dilution spiral. Cash is A$2.28m with about A$3.4m per year of outflows at FY26 rates. The share price is at 0.2–0.3c, there are over 726m out-of-the-money options, and Advent itself discloses insufficient working capital.

  3. Governance and related-party structure. Capital flows from public shareholders to unlisted entities overseen by the same chairman. There is one formal board meeting a year, no D&O insurance and accrued unpaid director fees. Valuation marks on unlisted holdings are not market-tested.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
By 31 Oct 2026September quarter Appendix 4C: cash balance and Advent loan advances
Nov 2026 (expected)AGM: remuneration vote, capital authority, director re-elections
By Nov 2026CHT US$2.5m capital raise completion; SPAC counterparty announcement
Nov–Dec 2026Expiry of 5m (30 Nov) and 10.7m (27 Dec) 3c options
Not setFull Court listing and hearing date for the PEP-11 appeal
Not setNOPTA decision on the PEP-11 renewal application (50% area)
OngoingOnshore Energy DOCA implementation and DMPE response
OngoingBARM 2.0 MVP completion, safety testing and first trial enrolment
10 Feb 2027Expiry of 710.7m 3c options
16 Feb 20271H FY27 results: further credit losses or fair-value movements
Any timeNew equity raise: size, price and dilution

Analyst verdict

BPH Energy is not an operating business. It is a thinly governed capital conduit whose value rests almost entirely on the outcome of one contested regulatory and legal question: whether PEP-11 survives. FY2026 marked the point at which accounting caught up with that reality.

The A$7.0m expected credit loss and A$2.2m associate loss cut net assets by over a fifth, to A$30.4m. The 17 June 2026 Federal Court judgment removed the principal near-term route to reinstating the permit. The court's finding that the public-interest ground independently justified refusal is the most important sentence in the judgment, because it narrows the appeal's prospects even where procedural unfairness was established.

Against this, the market already prices BPH at roughly one-seventh of book value. At about A$4m market capitalisation, it is valuing the PEP-11 option, the CHT stake and options, Cortical and MDS at little or nothing. That is the essence of the bull case: any positive surprise would be large relative to the equity value. Possible surprises include a successful appeal, a NOPTA renewal over half the permit area, or a CHT liquidity event at the indicated US$3,000 per share.

The structural problems are, however, real and persistent:

Funding: Cash covers well under a year of operating plus investee-lending outflows at FY26 rates.

Capital raising: Further equity must be raised near 0.2–0.3c, against a share register that has already doubled since 2020.

Valuation and control: Unlisted holdings are marked without market tests. Capital deployment decisions concentrate in a single executive who also sits on the boards of the borrowers.

Overall assessment: a high-risk, binary special situation suitable only for speculative capital with a view on the PEP-11 appeal or on CHT's listing pathway. The base case for the next 12 months is further dilution and continued book-value erosion, absent a favourable Full Court or NOPTA outcome. Monitor the September quarter cash balance, the CHT raise and the appeal timetable as the decisive near-term signals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureAge (FY26 AR)BackgroundOther directorships

David Breeze

Executive Chairman, Managing Director and Company Secretary

Company Secretary since 23 Nov 2016. Director since the early years of the company; appointment date not disclosed in reviewed documents

72

Corporate finance specialist; former corporate consultant to Daiwa Securities; executive and director roles in stockbroking. Says he has structured, raised capital for and listed over 70 companies (over A$250m raised). B.Econ, MBA, Fellow of the Australian Institute of Company Directors

MEC Resources (listed, Apr 2005–present); Grandbridge Ltd, Cortical Dynamics, Molecular Discovery Systems, Diagnostic Array Systems, Advent Energy and its subsidiaries (unlisted)

Anthony (Tony) Huston

Non-Executive Director

Jun 2017–present

71

45+ years in on- and offshore hydrocarbon engineering. Managed JFP NZ International (jack-up rig in NZ waters) in the 1990s; founded his own exploration and production company in 1996; recent focus on enhanced-recovery technology (US, Mexico, Oman, Italy, Turkmenistan)

Clean Hydrogen Technologies (investee); MEC Resources (listed)

Charles Maling

Non-Executive Director

Appointment date not disclosed in reviewed documents

72

Former Communications Officer, WA Environmental Protection Authority (8 years); 14 years at the WA Department of Environment. Bachelor of Sociology and Anthropology

Grandbridge Ltd (unlisted)

Directors' Remuneration

Person (AUD)Salary/fees FY2025Salary/fees FY2026Share-based (other) FY2026Performance rights expense FY2026Total FY2025Total FY2026

D Breeze

148,000148,0007,450475,600678,109631,050

C Maling

25,00025,0000027,80725,000

A Huston

35,00025,000278038,60925,278

Total

208,000198,0007,728475,600744,525681,328

Governance Overview

FeaturePosition

Board size

3

Independence

Maling is the most plausibly independent director. Huston sits on the board of investee CHT and of MEC Resources, which compromises independence under ASX Corporate Governance Principles. Breeze is executive

Chair/CEO separation

None. Chairman, Managing Director and Company Secretary are the same person

Committees

No separate audit, remuneration or nomination committees disclosed; functions are handled by the full board. Corporate Governance Statement is on the website

Meetings

One formal board meeting in FY26. Business is conducted informally by telephone, with decisions by circular resolution (FY26 AR)

Related-party intensity

High. The chairman is a director of Advent, Cortical, MDS and MEC, which are the principal recipients of BPH capital and loans

Major Shareholders

HolderSharesApprox. % of about 1.35bn shares

D Breeze (including Grandbridge Ltd)

69,750,8055.2

A Huston

9,438,0700.7

C Maling

7,337,4280.5

Directors combined

86,526,3036.4

Competitive Landscape

Competitors by Segment

ArenaCompetitorTypeRelative positioning

East-coast gas supply (vs PEP-11)

Santos (Narrabri)

ASX large-cap

Onshore NSW gas project with approvals; vastly larger resources

—

Beach Energy

ASX mid-cap

Producing east-coast gas supplier

—

Amplitude Energy (formerly Cooper Energy)

ASX

Producing Gippsland/Otway gas

—

Comet Ridge

ASX small-cap

Queensland gas appraisal

—

LNG import terminal proponents (e.g., Squadron Energy, Port Kembla)

Private / infrastructure

Alternative NSW supply source

—

Bounty Oil & Gas

ASX micro-cap

PEP-11 JV partner (aligned, not competing)

Brain / anaesthesia monitoring (vs Cortical)

Medtronic (BIS™)

Global medtech

Market-leading depth-of-anaesthesia monitor

—

Masimo (SedLine®)

Global medtech

EEG sedation monitoring

—

GE HealthCare (Entropy™)

Global medtech

Integrated monitoring

—

Philips and other OEM monitor makers

Global medtech

Integration targets as much as competitors

Methane pyrolysis / turquoise hydrogen (vs CHT)

Hazer Group (ASX: HZR)

ASX small-cap

Iron-ore-catalyst methane pyrolysis with graphite co-product; most direct listed comparable

—

Monolith

Private (USA)

Plasma pyrolysis, carbon black

—

Modern Hydrogen; Ekona Power

Private

Pyrolysis start-ups

—

Steam methane reforming with carbon capture, and electrolysers

Incumbent / alternative

Main cost benchmark

Peer Comparison FY2026

MetricBPH EnergyBounty Oil & GasMEC Resources

Listing

ASX

ASX

ASX

Latest FY revenue

A$1.04m finance income (FY26)

——

Revenue growth

+24.6% (FY26)

——

Net margin

−975% (FY26)

——

R&D intensity

0% (investee-level only)

Not applicable

Not applicable

PEP-11 exposure

Indirect, 35.8% of Advent's 85%

Direct 15%

Indirect, related to Advent

Company Snapshot

2

Employees

2001

Founded

Stirling, Australia

Headquarters

SWOT Analysis

Strengths

  • Large resource optionality. PEP-11 has a P50 prospective resource of 5.7 Tcf gross and 4.9 Tcf net to Advent (FY26 AR), close to Australia's largest gas market.
  • Debt-free balance sheet. Borrowings are only A$65k, an interest-free unsecured facility (FY26 balance sheet).
  • Low and falling overhead. Administration fell 25% to A$417k in FY26, and operating cash burn fell 44% between FY23 and FY26.
  • Diversified venture exposure. BPH holds stakes across gas (35.8%), hydrogen (16.1% plus 760 options), medtech (16.3%) and biotech (20%).
  • Cortical has regulatory track record. First-generation BARM gained TGA approval, Korean MFDS approval and a CE mark, with 36 granted patents (FY22 4E).
  • Partial procedural vindication. The Federal Court found Asset Energy was denied procedural fairness over undisclosed well costings (17 Jun 2026 judgment), which provides a potential appeal ground.

Weaknesses

  • Book value is collapsing. Net assets fell from A$38.49m to A$30.43m (−21%) in FY26, with a net loss of A$10.16m.
  • Concentrated credit exposure to one related party. A$7.02m expected credit loss in FY26. Loans of about A$3.7m per year have gone to Advent, where BPH's chairman is a director.
  • Earnings quality is low. Only A$127k of A$1.04m "finance income" was received in cash in FY26.
  • Governance is thin. Three directors, one formal meeting in FY26, a combined Chair/MD/Company Secretary, and no directors' and officers' insurance.
  • Accrued unpaid director fees of A$625k at FY26 (A$521k at FY25).
  • Severe dilution history. Shares on issue rose from 373m (FY20) to 665m (FY21) to about 1.35bn (FY26). Over 726m options are also outstanding at 3c, about 10 times the share price.

Opportunities

  • Full Court appeal of the 17 Jun 2026 judgment could reinstate PEP-11 rights.
  • NOPTA renewal application over 50% of PEP-11 (Mar 2025) offers a separate, non-litigious path.
  • CHT NASDAQ SPAC listing could create the first liquid mark for BPH's 16.1% stake. The current raise is priced at US$3,000 per share.
  • CHT data-centre demand: Horizon Fuel Cells LOI (USA) and a Singapore electricity generation company letter of support.
  • BARM 2.0 trials in the USA and the Netherlands, followed by FDA submission. US advisory board and Henry Ford and Mayo Clinic links.
  • East-coast gas supply shortfalls could shift political calculus on NSW offshore gas over time.

Threats

  • Loss of PEP-11 tenure would trigger a A$16.8m write-off of capitalised exploration in Asset Energy (FY26 AR), largely impairing BPH's Advent investment and loans.
  • Public-interest refusal ground was upheld independently, which is a high bar to overturn on appeal.
  • Funding gap: cash of A$2.28m against about A$3.4m of annual operating plus net investing outflow (FY26 run-rate).
  • Advent's own going-concern risk. BPH discloses that Advent's directors believe Advent's working capital will not be sufficient to fund its operations (FY26 AR).
  • Onshore Energy administration (Apr 2026) signals deterioration across Advent's portfolio.
  • Share price at a 0.2–0.3c floor (52-week range 0.2–2.2c) constrains further equity raising, given dilution.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025Advent applies to NOPTA for PEP-11 renewal over 50% of the permit areaSecond path to tenure; still pending
17–18 Jul 2025Cortical showcases BARM 2.0 at the Australia Regulatory Device Summit (FDA, TGA, ANVISA, HSA, PMDA attending)Regulatory engagement
27 Aug 2025FY25 results: net profit A$6.79m, driven by a A$6.93m fair-value gainPeak reported earnings and net assets (A$38.5m)
27–28 Aug 2025Cortical exhibits at MedTech on the Hill, Parliament House, CanberraPolicy visibility
16 Sep 2025Federal Court hearing adjourned; Justice Jackson directs the hearing to proceed in NSWDelay of about 5 months
1 Oct 2025Cortical presents at Renaissance VC Un-Demo Day, DetroitUS investor access
Early Oct 2025Cortical visits Henry Ford Innovations, DetroitUS clinical partnering
29 Oct 2025622.4m listed BPHO options (3c) expire unexercisedLost potential funding of about A$18.7m if exercised
28 Nov 2025AGM approves FY25 remuneration report, new options and director option issuesGovernance
2–3 Dec 2025Options prospectus issued (1-for-1 replacement new options at A$0.001)Capital management
27 Dec 202510.66m new options issued to directors (subscription set off against fees owed)Director participation
1 Jan 2026BPH and CHT agree replacement options (760 outstanding at US$3,000)Preserves CHT upside
12 Jan 2026A$1.208m placement at A$0.009 (134.2m shares, 1:1 attaching options) announced; issued 20 JanLiquidity
28 Jan 2026December quarter 4CRoutine
3 Feb 2026Options offer closesCapital
5 Feb 2026Cortical repays A$876,597 of its BPH loan from R&D tax refundRare cash inflow
10 Feb 202658m performance rights issued to D. Breeze (approved at 2023 AGM)Incentive tied to PEP-11 outcome
16 Feb 2026542.9m new options issued (A$542,891 raised); expiry 10 Feb 2027Working capital
17 Feb 2026Half-year: net loss A$925,691; net assets A$37.8m; material uncertainty flagged over Advent investment and loansEarly warning
20 & 23 Feb 2026PEP-11 judicial review heard in the Federal Court, SydneyKey legal event
Mar 2026Cortical at the Wholesale Investor Emergence conference (1,400+ attendees) and the Mayo Clinic Melbourne presentationProfile
~8 Apr 2026Governance
10 Apr 2026Advent's Onshore Energy enters voluntary administrationWrite-down of northern Australian assets
30 Apr 2026March quarter 4C: cash A$3.59m; operating outflow A$231kLiquidity
12 Jun 2026BPH announces judgment due 17 Jun 2026Market signal
17 Jun 2026Trading halt. Federal Court dismisses the PEP-11 judicial review. It finds Asset Energy was denied procedural fairness on undisclosed well costings, but that this was immaterial because the public-interest ground independently justified refusal. Parliamentary privilege barred challenge to the truth of NSW Parliament statements relied on as community viewsMajor adverse event
19 Jun 2026BPH formally announces the judgmentShare price falls to about 0.3c
3 Jul 2026Advent and Asset Energy announce intention to appealLitigation continues
13 Jul 2026Notice of appeal lodged with the Full Court of the Federal CourtAppeal live; hearing timing set by the court
24 Jul 2026Onshore Energy Deed of Company Arrangement approved by creditorsRestructuring
29 Jul 2026June quarter 4C: cash A$2.281m; large investing outflow to related entities; 38.7 quarters of funding statedLiquidity
21 Aug 2026Advent Energy June 2026 financial statements released to ASXInvestee disclosure
28/31 Aug 2026FY26 results: net loss A$10.16m; A$7.02m expected credit loss; net assets A$30.43mReset of book value
FY26 (exact date not disclosed)Cortical appoints Lt Gen R. Cloutier (Ret) and Brig Gen S. Bagby (Ret) as its founding US advisory teamUS commercial strategy
Sep–Oct 2026No further material announcements verified. September quarter 4C due by 31 Oct 2026; AGM expected around Nov 2026 (date not confirmed)Monitor

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Finance income / revenue rose from AUD 0.2 Mn in FY2022 to AUD 1 Mn in FY2026.
BPH Energy Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Finance income / revenue0.20.30.80.81

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BPH Energy Ltd, Appendix 4E and Annual Financial Report FY2026 (signed 28 Aug 2026; lodged 31 Aug 2026)
  2. BPH Energy Ltd, Appendix 4E and Annual Financial Report FY2025 (27 Aug 2025), ASX announcements platform
  3. BPH Energy Ltd, Appendix 4E FY2022 (31 Aug 2022), ASX
  4. BPH Energy Ltd, Appendix 4D Half-Year Report to 31 Dec 2025 (17 Feb 2026), ASX
  5. BPH Energy Ltd, ASX announcements: 12 Jun 2026, 19 Jun 2026, 3 Jul 2026 and 13 Jul 2026 (PEP-11 updates); Quarterly Activities / 4C reports of 28 Jan 2026, 30 Apr 2026 and 29 Jul 2026
  6. Aggregators, used only where flagged: StockAnalysis (ASX:BPH), Stockopedia, InvestSMART, Google Finance, TipRanks, Kalkine Media, financialfilings.com, roic.ai

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.